Study for adults with Chronic Myeloid Leukemiaa (CML)


17005

A phase II randomized, multicenter study of treatment-free remission in chronic myeloid leukemia in chronic phase (CML-CP) patients who achieve and sustain MR4.5 after switching to nilotinib

Medicine

Douvas Michael, G

UVa Health System, Division of Hematology Oncology seeks adults with Chronic Myeloid Leukemia (CML) for a research study. To be eligible you must still have leukemia cells in your blood after at least one year of treatment with imatinib (Gleevec®) The purpose of the study is to find out if the study drug called nilotinib (Tasigna®) will decrease the number of leukemia cells. All participants in this research study will receive nilotinib (Tasigna®) by mouth twice a day. The study involves clinic visits, blood draws, EKG recordings of heart activity, questionnaires, and possible bone marrow sample collection. Participation in the study requires up to about 40 visits to the clinic over a period of up to 7 years. ? Nilotinib (Tasigna®), study-related EKGs and blood tests will be provided at no charge to you ? There is no additional compensation for participation For more information please contact: • Kim Underwood, Study Coordinator, at (434) 982-3947 or km3q@virginia.edu • IRB-HSR # 17005 Principal Investigator: Michael Douvas, MD

Hematology/Oncology

Adult

Leukemia

Cancer (Oncology)

Ill

No Compensation

Kim Underwood

km3q@virginia.edu

4349823947